Fibroblast Activation Protein Inhibitor PET/CT Imaging in Malignant Tumor of Digestive System

Last updated: July 13, 2023
Sponsor: Zhongnan Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Colon Cancer; Rectal Cancer

Colorectal Cancer

Neoplasms

Treatment

Fibroblast activation protein inhibitor PET/CT imaging

Clinical Study ID

NCT05420558
ZNYYPTXM2022013
  • Ages 18-80
  • All Genders

Study Summary

The purpose of this single center prospective study is to assess the value of FAPI PET imaging in predicting early postoperative recurrence of malignant tumor of digestive system and to evaluate the diagnostic performance of FAPI PET/CT in the detection of primary tumor and metastatic lesions.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Voluntarily participate and sign the informed consent.
  2. Patients with suspected or new diagnosed gastrointestinal cancer or other malignanttumor of digestive system.
  3. Complete clinical information, biochemical examination results, CT and/or MRI imagingexamination, pathological information, and clinical/imaging follow-up data.

Exclusion

Exclusion Criteria:

  1. Female patient who plan to become pregnant within 6 months, or pregnant orbreast-feeding women.
  2. Allergic constitution.
  3. Those who are in poor general condition and cannot tolerate PET/CT examination.
  4. The researchers believe that he or she is not suitable to participate in this study.

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: Fibroblast activation protein inhibitor PET/CT imaging
Phase:
Study Start date:
June 23, 2022
Estimated Completion Date:
December 31, 2023

Study Description

Malignant tumor of digestive system is one of the most common cancer types worldwide with high cancer-related mortalities. FDG PET/CT is an essential imaging modality in the tumor treatment and management. However, FDG PET/CT has certain limitations. For example, the detection sensitivity and tracer uptake in signet ring cell carcinoma (SRCC) is low. Furthermore, the physiological uptake of the gastrointestinal tract and acute gastroenteritis may mask the detection of lesion in the abdomen and pelvis. Therefore, a novel molecular imaging tracer is needed for the accurate evaluation of malignant tumor of digestive system.

Cancer-associated fibroblasts (CAFs) specifically express fibroblast activation protein (FAP), which is highly expressed by CAFs in more than 90% of human epithelial cancers. FAP-specific small molecule inhibitors (FAPIs) show much advantages over FDG, including high tumor accumulation, low background tissue uptake, and rapid clearance in vivo.

The purpose of this single center prospective study is to assess the value of FAPI PET/CT imaging in predicting early postoperative recurrence of malignant tumor of digestive system and to evaluate the diagnostic performance of FAPI PET/CT in the detection of primary tumor and metastatic lesions.

In this study, qualitative and quantitative analyses will be used. The diagnostic criteria of FAPI PET/CT: if the FAPI uptake of lesion is higher than that of the surrounding background tissue, it is determined as a positive lesion; if the FAPI uptake of the lesion is the same as or lower than that of the surrounding background tissue, it is determined as a negative lesion. Pathological result is used as the gold standard for diagnosis. The diagnostic performance of FAPI PET/CT including sensitivity, specificity, positive predictive value, negative predictive value, and accuracy will be calculated.

The quantitative indicators include the following metabolic parameters: maximum standard uptake value (SUVmax), mean standard uptake value (SUVmean), tumor metabolic volume (MTV), total tumor glycolysis (TLG), tumor-to-liver ratio, and tumor-to-background tissue ratio.

Connect with a study center

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei 430071
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.